Forum

NEW CLINICAL TRIAL IS AVAILABLE FOR VITILIGO

We are pleased to share news about a new nationwide clinical trial for vitiligo. The name of the trial is “An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects with Non- Segmental Facial Vitiligo”. The study will be conducted by Aclaris Therapeutics, Inc. and will test their investigational study drug ATI-50002  as a topical solution for vitiligo. You can read more information on using this family of drugs, called JAK inhibitors, for vitiligo here:
https://go.umassmed.edu/e/184882/vitiligo-jak-inhibitor-update-/l9sgs8/1224585653
 
In order to qualify for this study, you must meet a certain set of requirements, known as inclusion criteria. Some of the key inclusion criteria are as follows:

1. You are 18 to 65 years of age
2. You have been diagnosed with non-segmental vitiligo by a healthcare professional
3. You have white areas on your face which, when added up, cover an area roughly half the size of your palm or larger
4. You may have vitiligo on other parts of your body besides face; however, you won’t be allowed to treat it.
5. You agree to discontinue all treatments you use to treat vitiligo while you are participating in the clinical trial, including creams, phototherapy, and any oral medicines

This trial is now seeking to enroll 24 eligible patients nationwide. It will last for 28 weeks and requires a total 11 visits to the clinic over the course of the study. It is an open-label pilot study, meaning that every patient enrolled will receive the investigational study drug for duration of the trial.
 
The goal of this study is to determine whether patients regain the pigment in vitiligo spots on the face after 6 months of applying the study drug. We will also record the safety and tolerability of the medication.
 
The Vitiligo Clinical Trial is being conducted at 5 locations nationwide. The University of Massachusetts Medical School in Worcester, MA is one of the sites and is currently recruiting patients. Please contact us if you think this clinical trial may be right for you. These are the 5 sites corrently recruiting  subjects:
 
John Harris, MD, PhD
UMASS, Worcester, MA 01605
Contact: Karen Gallagher- Dorval , RN  clinicaltrialsunit@umassmed.edu;
508-856-2800
 
Amit Pandya, MD
UT, Southwestern, Dallas, Tx
Contact:  Orlando Martinez oralndomartinez@UTSouthwestern.edu
 
Stacy Smith, MD
Encinitas, CA
Contact:  aowens@cdcrinstititute.com
760-990-1965
 
Pearl Grimes, MD
Los Angeles, CA 
Contact: Rama Nashawati or Sana Ijaz research@pearlgromesmd.com
323-467-4389 x 221
 
Kappa Meadows, MD
Lynchburg, VA 24501
Contact: sfoster@educationandresearch.com
323-467-4389 x 221
 
 
Because participants in this study will be required to attend multiple clinic visits over the course of the study, you should contact the site closest to you.

For information about this study at The University of Massachusetts Medical School in Worcester, MA, please call our Clinical Research Coordinator, Karen Gallagher- Dorval , RN at 508-856-2800 or via email at clinicaltrialsunit@umassmed.edu

We are excited to start this new clinical trial in vitiligo patients, and we are working on more trials that we hope to start soon. So, if you do not qualify for this trial, there will be more to come! Keep an eye out for more notices, which will come through additional newsletters.

Sincerely,

 http://go.umassmed.edu/l/184882/2017-07-14/h3kkz/184882/16381/john_harris.png" width="100" class="CToWUd"/>
DR. JOHN E. HARRIS, MD, PhD
Associate Professor of Dermatology,
Director of the Vitiligo Clinic and Research Center
at University of Massachusetts Medical School